Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 7 to 12 years old (inclusive)~* Amblyopia associated with strabismus, anisometropia, or both~* Visual acuity in the amblyopic eye 19 to 71 letters on Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS©) (20/40 to 20/400 inclusive)~* Visual acuity in the sound eye 79 letters or better on E-ETDRS© (20/25 or better)~* Interocular difference \>=15 letters (3 lines)~* Spectacles, if needed, worn for at least 16 weeks or visual acuity documented to be stable~Inclusion Criteria for Optional Ancillary Study:~* Enrolled into the main study~* Refractive error in both eyes between -0.25 and +5.00D, inclusive (to avoid the need to adjust for refractive error)~* Birth weight \>1500 grams~* No history of Central Nervous System (CNS) disease (e.g. intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), meningitis, developmental abnormalities of the brain, hydrocephalus, cerebral palsy, hypoxic ischemic encephalopathy~Exclusion Criteria:~* Amblyopia treatment (other than spectacles) in the last 6 months~* Myopia (more than -0.25D spherical equivalent) in either eye

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Patching (Type: ACTIVE_COMPARATOR): Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and \>4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
- Atropine (Type: ACTIVE_COMPARATOR): Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)

Based on this trial design, predict the completion outcome and termination type (if applicable).